Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Monday that its third quarter revenues rose 84 percent year over year driven by a strong increase in billable tests.

For the three-month period ended Sept. 30, the Temple City, California-based company posted revenues of $10.3 million compared with $5.6 million a year ago. The number of billable tests delivered in the quarter grew 272 percent to 20,697, Fulgent said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.